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ABSTRACT 
Infantile Hypertrophic Pyloric Stenosis (IHPS) is a condition of early infancy characterized by 
thickening of the pyloric muscle resulting in obstruction of gastric outflow. It affects 1-3/1000 
live births and is one of the most common causes of gastrointestinal obstruction in infants. 
IHPS is developed under influence of both genetic and environmental factors, but the exact 
pathogenesis is unknown. The aim of this thesis was to elucidate genetic and environmental 
factors contributing to development of IHPS. 
 
In study I and II we used a candidate gene approach to study association of two different genes 
with potential involvement in pathogenesis of IHPS. Since treatment with the motilin agonist 
erythromycin gives an increased risk for IHPS, we proposed the GI-hormon motilin as an IHPS 
candidate gene (study I). Sequencing of the MLN coding exons revealed three previously not 
reported sequence variants occurring in both cases and controls, though without obvious 
association to the disease. In addition, no significant association was found between the 
rs2281820 (p.Val15Ala) polymorphism and IHPS. Neuronal nitric oxide synthase encoded of 
NOS1 is key player in the pathway mediating pyloric relaxation, and is suggested as a IHPS 
susceptibility gene. A functional NOS1C promoter polymorphism (c.-84G>A; rs41279104) 
regulating expression of the gene was genotyped in cases and controls (study II). We could not 
confirm a previously reported association of the A-allele with IHPS in our material.  
 
In study III we used an unbiased strategy, genome wide linkage analysis, to search for 
chromosomal regions harboring candidate genes. 37 Swedish IHPS families were analysed in 
an initial genome wide scan revealing seven regions of interest for fine mapping. Fine mapping 
using a statistical model with equal weight to all families identified significant linkage to 
2q24.3, and suggestive linkage to 7p22.2 and 12q24.23. The statistical model using a weighting 
scheme to compensate for different pedigree structures identified significant linkage to 2q24.3 
and 7p21.3, and suggestive linkage to 6p21.31. Interestingly, these candidate regions harbor the 
previously suggested candidate genes MLN and NOS1. Two novel proposed candidate genes, 
NPY and GCG, were sequenced without obvious pathological findings. Extending the material 
with additional 31 British IHPS families in the fine mapped regions did not enhance the NPL 
score. 
 
In study IV we performed a nationwide register study based on all IHPS cases in Sweden 1973-
2008, yielding a study cohort of 3608 cases and 17588 matched controls. Incidence fell from 
2.25 to 0.43/1000 between years 1988-1998 with a relatively constant sex ratio of 5:1 boys to 
girls. Study variables associated with an increased risk for IHPS in our material were caesarian 
delivery, prematurity, neonatal jaundice and being first born. Maternal smoking, low maternal 
age and Nordic ethnicity were also associated with increased IHPS risk. Maternal smoking and 
low birth rank were stronger risk factors during period with low incidence. Prematurity was a 
stronger risk factor when analysis was stratified for late onset of disease.  
 
In summary we have identified candidate gene regions on chromosome 2, 6, 7 and 12 and 
identified several epidemiological risk factors for IHPS. 
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1 INTRODUCTION 
 
The pyloric muscle is a sphincter defining the transition between the stomach and 
duodenum. The term pylorus means ”gatekeeper” formed by the greek words pyle 
(gate) and ourus (guard), giving a good description of the pylorus two main functions: 
control the outflow from the stomach preventing passage of large pieces of food to the 
duodenum, and to prevent backflow of intestinal content to the stomach. 
 
 
 
Figure 1.  Sagittal section illustrating the relationship between stomach, pylorus and 
duodenum. Gray’s anatomy of the Human Body, 1918  
 
The pyloric sphincter consists of two smooth muscle layers, a thin outer longitudinal 
layer and a thicker inner circular layer exerting the sphincter function (Ramkumar and 
Schulze 2005). Its activity is controlled by a complex mechanism including both 
neuronal and hormonal pathways (Daniel et al 1994, Fisher et al. 1973, Shafik et al 
2007).  
 
Infantile hypertrophic pyloric stenosis (IHPS) is a paediatric condition, in which the 
pylorus becomes abnormally thickened caused by pyloric muscle hypertrophy as 
shown in Figure 2. Histological studies of IHPS samples describe true muscle 
hypertrophy mainly of the circular layer with little or no hyperplasia (Tam 1985, Abel 
et al. 1998). The disease occurs only during a limited age span, with onset ranging from 
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one to approximately twelve weeks of age. The thickening of the pyloric sphincter 
causes a nearly complete obstruction of the gastric outlet, which prevents gastric 
emptying. Consequently, the affected infant presents with projectile vomiting after 
feeding which untreated can cause severe illness within a few days. In the past IHPS 
often had a lethal outcome, but today mortality is negligible. The surgical procedure 
relieving the pyloric obstruction, Ramstedt’s pyloromyotomy presented in 1912, has 
been described as one of the greatest advances in pediatric surgical history since it has 
saved so many lives.  
 
 
 
Figure 2. Schematic illustration of pyloric hypertrophy before and after Ramstedt’s 
pyloromyotomy. The hypertrophic pyloric muscle is incised down to the mucosa, 
which bulges out through the muscular incision relieving the obstruction.  
 
The incidence of IHPS varies between populations, and is most common in Caucasians 
with a frequency of to 1.5-3 per 1000 births (Persson et al 2001, Mitchell and Risch 
1993). Interestingly, there is a striking predominance of affected boys with a sex ratio 
of 4-5 affected boys per one girl, giving an incidence of 1 per 2-300 male births and 1 
per 1-2000 female births (Rimoin et al 2007, Krogh 2010). A trend of decreasing 
incidence is reported from several European countries including Sweden during the last 
decades (Persson et al 2001, Hedbäck et al 2001, Sommerfield 2008, Pedersen et al 
2008). However, IHPS is still one of the most common causes of gastrointestinal 
obstruction in infants and one of the most common diagnoses requiring surgery during 
the first months of life.  
 
Although IHPS is sometime referred to as a congenital disease, it has been shown that 
the pyloric muscle is normal at birth in infants later presenting with the disease 
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(Wallgren 1946, Rollins et al 1989). An interesting aspect is that the pyloric 
hypertrophy, and subsequently the symptoms, spontaneously resolves after a few weeks 
to months if the infant meanwhile can be cared for and kept alive with conservative 
treatment (Tallerman 1951, Swift and Prossor 1991).  
 
The underlying mechanism causing the disease is still unknown, but a multifactorial 
background is well established where a combined influence of genetic and 
environmental factors contributes to the disease (Mitchell and Risch 1993, Chakraborty 
1986). Studying both the molecular background and the environmental factors 
involved, can give a better understanding of the pathophysiology and possibly also lead 
to identification of environmental risk factors which both can be targets for preventive 
measures.  
 
 
HISTORICAL BACKGROUND 
The first clinical report of a probable case of IHPS was published in 1627 by Hildanus, 
who described an infant suffering from ”spastic vomiting”. Anatomical descriptions of 
pyloric hypertrophy can be found back in the early 1700s in a publication by Blair who 
in 1717 reported the clinical history and autopsy record of a case of pyloric stenosis 
(Hernanz-Schulman 2003, Kellett 1933). In 1788 Beardsley wrote the report “A case of 
scirrus in the pylorus of an infant”, which was the first American publication describing 
the disease (Caulfield 1930). However, it was not until 100 years later IHPS became a 
clinical entity that attracted scientific attention. This after the Danish pediatrician 
Hirschsprung reported two patients with convincing clinical and pathological features 
of the disease in his seminal article in 1888 (Hirschsprung 1888, Hernanz-Schulman 
2003).  
 
In the beginning of the 1900s, IHPS was “more or less equal to a death sentence” and 
mortality rates exceeded 50% well into the 1920s (Carter 1961). Efforts were made to 
keep the infants alive by frequent small feedings until the pyloric muscle hypertrophy, 
and so the symptoms, spontaneously resolved after a few weeks to several months. Yet, 
the surviving children often suffered from consequences of the severe malnutrition 
associated with the disease (Klein and Forbes 1975). Oral atropine treatment with 
purpose to relieve the pyloric spasm was to some extent successful (Svensgaard 1935). 
However, it was the introduction of pyloromyotomy, together with improvements in 
anaesthetic technique and perioperative care, that significant improved the prognosis of 
survival and led to the decreased rate of mortality (Carter 1961).  
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The first report describing an attempt to operate IHPS dates back to 1892 when Cordua 
performed a jejunostomy in a patient with IHPS that unfortunately did not survive 
(Cleon and Nafe 1947). In 1898 Meyer successfully introduced gastro-enterostomy as 
an IHPS treatment (Solowiejczyk et al 1980). It became a quite successful strategy and 
the most frequent used procedure until the early 1900s, even though it was associated 
with over 50% mortality (Taylor 1959). The gastro-enterostomy era was followed by a 
less extensive procedure, pyloroplasty that was introduced in 1903 by Dent. The 
pylorus was then incised longitudinally down through the muscle and mucosa, and 
sutured transversally (Taylor 1959). Burghard in 1906 introduced a different technique 
by using Hegar’s dilators introduced through an incision in the stomach to induce 
dilation, or rather divulsion, of the pyloric muscle from the inside (Taylor 1959). In 
1907 Fredet performed the first extra-mucous pyloroplasty, but still suturing the muscle 
layer transversely as in the original pyloroplasty. Meanwhile and independently from 
Fredet, an almost identical technique was developed in 1908 by Weber. The Fredet-
Weber procedure was modified by Conrad Ramstedt in 1911, partly by coincidence, 
when he left the pyloric muscle unclosed since the sutures cut through the muscle 
edges. In 1912 his method “Ramstedt pyloromyotomy” was published (Ramstedt 
1912), and is still today used as the golden standard procedure and treatment of choice. 
 
 
CLINICAL ASPECTS 
IHPS usually presents at 2-8 weeks of age with intense, projectile nonbilious vomiting 
as dominating symptom. Onset beyond three months of age is rare, and the disease 
virtually does not exist after 1 year of age. Since the affected infant only can pass very 
limited amounts of fluid to the intestine for absorption, dehydration and weight loss are 
rapidly encountered. The combination of dehydration and loss of gastric juice promptly 
results in disturbed electrolyte balance and metabolic acidosis. A few percent of the 
patients develops jaundice due to adverse effect of starvation on hepatic glucuronyl 
transferase activity, which resolves after surgery (O’Neill et al 2004). If left untreated, 
the infant can become severe ill within only a few days.  
 
The typical history of sudden onset of projectile, nonbilious vomiting in an infant 
within the age span of one to a few months, gives a strong clinical suspicion of IHPS. 
Occasionally, the hypertrophic pyloric muscle can be palpated as an “olive “ when the 
infant is examined. In the past, this was a reliable diagnostic sign occurring in 70-90% 
of the cases (Pollock et al 1957, Scharli et al 1969, Grimes et al 1950, Hulka et al 
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1997). Today, only 20% of cases exhibit a palpable pyloric tumor and diagnostics rely 
more on radiologic investigation (Hulka 1997). It has been suggested the decreased 
frequency of palpable finding is due to earlier admission and thus a healthier and less 
emaciated infant (Hulka et al 1997). The standard diagnostic method is abdominal 
ultrasound, which can visualize the thick and elongated pyloric muscle. If ultrasound is 
inconclusive, an upper gastrointestinal study with contrast can be diagnostic.   
 
The preoperative care consists of intravenous rehydration and correction of electrolyte 
disturbances to get the infant in condition for surgery. Typically the infant can be 
operated on within one day after admission. The standard procedure is Ramstedt’s 
pyloromyotomy in which the pyloric muscle is incised down to the mucosa, and then 
left unclosed. This immediately relieves the obstructed gastric outflow and allows 
passage of stomach content to the duodenum. The pyloromyotomy can be performed 
either with laparotomy preferable through a small incision in the supraumbilical fold 
(Tan and Bianchi 1986), or as a laparoscopic procedure (Jia et al 2011). The 
postoperative course is usually uncomplicated with the infant reaching full enteral 
feeding within a few days. Most infants are discharged from the hospital within 2-3 
days post operatively.  
 
 
Figure 3. Hypertrophic pyloric stenosis after pyloromyotomy. Photo: Henrik Ehrén. 
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2 GENETICS IN IHPS 
 
Determining the genetic background of a disease includes observations of familial 
aggregation, estimation of relative risk and heritability, twin studies or finding of the 
genetic aberration causing the disease (Haines and Pericak-Vance 1998). IHPS exhibit 
obvious clustering in families, even though the majority of cases are sporadic (Krogh et 
al 2011, Carter 1961). Moreover, the inheritance pattern in familiar cases most often 
does not follow the laws of Mendelian inheritance (Chakraborty 1986). Twin studies of 
IHPS support the genetic background of the disease, but also imply the importance of 
environmental factors for the disease to occur (Krogh et al 2011, MacMahon 2006). 
These observations are all typical features of a complex disease and IHPS was already 
in the 1950s postulated to belong to this group of disorders. In fact, IHPS was one of 
the first and most thoroughly studied complex diseases when described in the today 
classic publications from Carter et al (Carter and Powell 1954, Carter 1961, Carter and 
Evans 1969) 
 
 
COMPLEX DISEASES 
In contrast to monogenic diseases caused by alterations in a single gene transmitted 
with simple Mendelian inheritance, complex disorders depends on interaction of 
multiple susceptibility genes with environmental factors and are not passed with 
Mendelian transmission. The features of multiple susceptibility genes and interaction 
with non-genetic factors explain why complex diseases often are referred to as a 
multifactorial, or polygenic diseases.    
 
A single susceptibility gene is neither necessary nor enough for causing a complex 
disease. Instead, susceptibility genes interact through an additive effect or through 
gene-gene interactions (epistasis) to reach the threshold for manifest disease. 
Susceptibility genes also interact, to a greater or smaller degree, with environmental 
factors. The genetic predisposition (liability) for the disease determines the response 
and effect of exposure to environmental factors that might trigger disease (Strachan and 
Read 2004).   
 
The concept of susceptibility and threshold for complex diseases is summarized in 
Figure 4. All individuals in a population have a susceptibility for a certain complex 
condition determined by multiple genes. Susceptibility is a continuous variable ranging 
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from high to low, and is in a population distributed as a Gaussian curve. Individuals 
whose susceptibility exceeds the threshold for disease, gets affected. As in the case for 
IHPS where the disease is more common in boys, the threshold value for girls is higher 
resulting in fewer affected girls. If the population studied consists of relatives to an 
affected individual, the whole Gaussian curve is shifted towards the threshold value. 
This results in a higher number of affected individuals in the “population of relatives to 
an affected” compared to the general population. The Gaussian curve of a population 
representing relatives to an affected girl is (in the case of IHPS) shifted more toward 
the threshold value compared the curve representing relatives to an affected boy 
(Strachan and Read 2004). 
 
 
Figure 4. A polygenic threshold model for a complex disease with sex-specific 
thresholds. (Figure adapted from Strachan and Read 2004). 
 
The number of susceptibility genes involved can range from just a few to a large 
number. The higher number of susceptibility genes involved the smaller contribution of 
each gene to the total risk of disease. From a gene mapping point of view, genes only 
contributing with a small risk are difficult to detect. Another phenomenon that 
complicates gene mapping is genetic heterogeneity, i.e. when two or more genes act 
independently in different individuals to cause an identical disease. (Ott 1990, Weeks 
and Lathrop 1995, Todd 2000). 
 
The recurrence risk of a monogenic disease can be calculated from the combination of 
transmission mode (dominant, recessive, X-linked) and the probability of the disease 
gene being passed from parents to the offspring. For complex diseases, the situation is 
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quite different, and calculation of recurrence risk is replaced by an empiric risk based 
on observations in the population (as in Table 1). This of course has a very low, or 
negligible correct predictive value. To foresee who will get affected will in most cases 
therefore not be better than a qualified guess (Strachan and Read 2004).  
 
Relative risk (λR) is commonly used to describe to which extent a relative of an index 
patient has an increased risk to be affected compared to the general population. λR is 
calculated as the ratio between the incidence among relatives to an affected individual 
and the general population incidence. R denotes the kind of relationship to the affected 
(sibling, son, daughter etc) and separate values of λR is calculated for each such group 
of relatives (R).  
 
Both genetic and environmental factors shared in a family can cause aggregation of a 
disease. Twin studies can be helpful to distinguish these two, and estimate to which 
extent the genetic and environmental factors contributes to the disease, respectively. 
Twins share environmental factors to a very large extent, and have either identical 
genetic background (monozygotic twins, MZ) or equaling a sib pair that in average 
share half of their genes (dizygotic twins, DZ). Higher concordance (both twins 
affected) in MZ twin pairs compared to DZ twins demonstrates the importance of 
genetic factors for development of the disease. Concordance not depending on zygosity 
suggests instead environmental factors of importance for development of the disease.   
 
 
FAMILIAL AGGREGATION AND TRANSMISSION OF IHPS 
Familial aggregation of IHPS is reported to occur in 13-14% of the IHPS cases 
(Persson et al 2001). As expected from a complex disease, IHPS transmission in 
general does not follow the Mendelian laws of inheritance. However, there are reports 
of families with a dominant transmission of the disease, sometimes referred to as 
families with monogenic form of IHPS (Fried et al 1981, Finsen 1979, Capon et al 
2006, Everett et al 2008a). Linkage studies in a few of these families have identified 
loci with evidence of linkage, but a specific disease causing gene has not been found in 
these regions (Capon 2006 et al, Everett et al 2008a).   
 
According to the polygenic threshold model summarized in Figure 4, children of IHPS 
affected mothers have a higher risk to be affected compared to children of affected 
fathers. Especially sons of affected mothers should have the highest risk, and this was 
also confirmed by Carter (1961) and Fuhrmann (1976) showing 21-23% of sons of 
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IHPS affected mothers were affected compared to 1-3 % of daughters of affected 
fathers. 
 
Table 1. Data of IHPS recurrence risks stratified for gender and relationship with the 
index patient (Data from Carter 1961). 
Index patient Sons Daughters Brothers Sisters 
Male  6.8% 1.2% 3.2% 3.0% 
Female  20.5% 11.1% 13.2% 2.5% 
 
With an incidence of 0.5% in boys and 0.1% in girls, data from Table 1 gives a relative 
risk λ ≈40 for sons to an affected mother and λ≈12 for daughters to an affected father. 
 
Krogh et al found a concordance rate of 46% in monozygotic twins compared to 8% in 
dizygotic twins, i.e. an almost 6-fold higher risk among MZ twins supporting the 
genetic background of the disease (Krogh et al 2011). Furthermore, IHPS showed a 
strong familial aggregation with heritability estimated to 87% and risk ratios of 19 for 
siblings, 29 for DZ twins and 182 for MZ twins, if an older sibling was affected. 
However, in this material no difference was found when inheritance was compared 
between male and female index patients (Krogh et al 2011). 
 
 
IHPS SUSCEPTIBILITY LOCI AND CANDIDATE GENES 
Genome wide linkage studies 
A few genome wide linkage studies are reported in the search for chromosomal loci for 
IHPS. Linkage was found to chromosome 16p12-p13 and 16q24 in two different 
multiplex pedigrees with dominant transmission (Capon et al 2006, Everett et al 
2008a). However, analysing these regions in other extended families did not confirm 
linkage, supporting IHPS being a disease with locus heterogeneity. The only genome 
wide linkage study of multiple families so far identified linkage to chromosome 11q14-
q22 and Xq23 in a material of 81 pedigrees (Everett et al 2008b).  
 
NOS1 gene  
To date, the neuronal nitric oxide synthase (nNOS) gene (NOS1) is the only gene 
reported with evidence as an IHPS susceptibility gene (IHPS1 MIM ID*163731), both 
by linkage and a proposed functional promoter SNP associated to the disease. The 
enzyme nNOS catalyzing synthesis of NO in enteric neurons, is a key player in the 
pathway mediating pyloric relaxation, which is thought to be deficient in IHPS patients. 
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Expression studies from pyloric tissue have indicated a down regulation of NOS1 
(Kusafuka and Puri 1997). Evidence of genetic linkage to NOS1 has been reported in a 
material of 27 IHPS families in a publication studying the NOS1 locus exclusively 
(Chung et al 1996). However, linkage could not be confirmed in a subsequent study 
comprising three IHPS families from a different population (Söderhäll and 
Nordenskjöld 1998).  
 
NOS1 has an extremely complex regulation of transcription with alternate promoters, 
alternative splicing, cassette insertions and deletions, varied sites for 3’-UTR cleavage 
and polyadenylation that produces different mRNA transcripts. This results in several 
different possible nNOS isoforms with different structural and functional properties 
(Wang et al 1999). A possible link between a functional NOS1 promoter polymorphism 
and IHPS was suggested by Saur et al (2004). Following the observation that 
predominantly the exon 1c mRNA isoform was decreased in IHPS pyloric tissue, the 
NOS1 exon 1c promoter region was sequenced revealing a previously uncharacterized 
SNP (c.-84A/G). This -84SNP A-allele had a 30% decreased promoter activity and was 
associated with IHPS, however only investigated in a small material consisting of 16 
patients.  
 
 
IHPS IN CHROMOSOMAL SYNDROMES AND GENETIC DISORDERS 
When a disease is associated with a chromosomal aberration or a genetic disorder, it 
can indicate a chromosomal region harboring susceptibility genes or in which pathways 
to search for these. IHPS is associated with a few chromosomal syndromes and 
disorders:  
 
Smith-Lemli-Opitz syndrome (SLOS) is an uncommon severe autosomal recessive 
disorder caused by mutations in the 7-dehydrocholesterol reductase gene (DHCR7) 
resulting in defective cholesterol synthesis (Kelley et al 2000). SLOS is characterized 
by facial dysmorphia, microcephaly, congenital heart disease, limb malformation, 
cholestatic liver disease, adrenal insufficiency and mental retardation (Craigie et al 
2005). IHPS was included as one of the SLOS characteristics in the original description 
of the syndrome, and occurs among 14-30% of the SLOS patients. This equals a 157-
fold increased risk compared to the population (Kelley 2000, Schechter et al 1997). 
Interestingly, early supplementary treatment with cholesterol seems to reduce the 
number of SLOS patients being affected of IHPS (Kelley 2000). If it is the defective 
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cholesterol synthesis itself that results in increased IHPS risk, or if it is some other kind 
of secondary SLOS manifestation is unclear (Schechter et al 1997).  
 
Partial duplication of chromosome 9q. IHPS is reported to be frequent among 
patients with a partial duplication of proximal chromosome 9q (Yamamoto et al 1988, 
Heller et al 2000, Maraschio et al 1998, Chung et al 1993). In general, genes for 
associated diseases are likely to be found at the breakpoints, which in this case would 
be at 9q22 and 9q31. A linkage study was also performed focusing on the 9q region in 
a material of 20 IHPS families but without providing evidence for an IHPS locus 
(Chung et al 1993).  
 
Trisomy 21. In trisomy 21, duodenal atresia is a frequently occurring gastrointestinal 
malformation (Choudry et al 2009). There are conflicting results whether infants with 
trisomy 21 also have an increased risk for IHPS (Knox et al 1972, Fabia and Drolette 
1970, Schechter et al 1997). None one of the published genetic linkage studies so far 
have reported evidence of linkage to chromosome 21.  
 
Phenylketonuria. An increased incidence of IHPS has been observed among infants 
with phenylketonuria (PKU) (Dodge 1975, Johnson et al 1978, Koch et al 1973). The 
classic form of PKU is an autosomal recessive disorder caused by mutations in the 
phenylalanine hydroxylase (PAH) gene. In presence of the co-factor terahydrobiopterin 
(BH4) PAH converts phenylalanine to tyrosine. Deficient PAH function results in 
accumulation and high levels of phenylalanine, which have a toxic effect on the brain. 
Consequences of untreated PKU include impaired mental development and seizures. 
Except from the classic form of PKU, other variants exist with mutations in genes 
encoding enzymes that control synthesis and recycling of BH4 (Scriver 2007). 
Interestingly, the BH4 deficient mouse model (hph1-mouse) exhibits a phenotype 
including transient pyloric hypertrophy. Supplementary BH4 has therefore been used 
experimentally to medically treat IHPS, however without success (Braegger et al 
1997). 
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3 STRATEGIES FOR FINDING SUSCEPTIBILITY 
GENES 
 
Different strategies can be used to search for susceptibility genes, and which one to use 
depends on several factors including study material available and knowledge of the 
pathogenesis of the disease. The candidate gene approach identifies a candidate gene 
based on a priori knowledge or hypothesis of its involvement in the pathogenesis, and 
explores if association to the disease can be found. Linkage analysis identifies unbiased 
and without prior knowledge of the pathogenesis, chromosomal regions linked to the 
disease, i.e. regions that might harbor susceptibility genes. When candidate regions are 
obtained from the linkage analysis, candidate genes are identified from these linked 
regions. Having a restricted chromosomal region to search in gives higher odds of 
finding the causative genes. 
 
The study populations used for candidate gene approach and linkage analysis are 
different. Candidate gene studies can utilize DNA samples from unrelated cases and 
healthy controls, to test polymorphisms for association or to screen the gene for 
mutations. For linkage analysis, DNA from whole families with aggregation of the 
disease is used. Large multiplex families with multiple affected are preferable, but these 
are often rare particularly when dealing with complex diseases. However, there are also 
linkage methods that can utilize materials with small families including only two 
affected, for example sib-pair analysis. Success of finding linked regions relies then of 
including as many families as possible in the analysis.  
 
 
LINKAGE ANALYSIS 
Basic idea of linkage analysis is to identify chromosomal regions segregating together 
with the disease in families. These linked regions are likely to harbor susceptibility 
genes. A primary advantage of linkage analysis is that no prior knowledge of 
physiology or biology underlying the disease is needed (Kwon and Goate 2000). 
During meiosis, genetic material from two homolog chromosomes is exchanged in a 
process called recombination. The closer two loci are located on a chromosome, the 
less likely will they be separated by recombination and instead segregate together to the 
next generation. The recombination fraction theta (θ) ranging from 0 to 0.5 is a 
measurement of how often recombination between two loci is likely to occur. Two loci 
are said to be completely linked (θ=0) if they always segregate together, never 
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separated by recombination. Two loci located far apart on a chromosome, or even at 
different chromosomes, are not linked with recombination fraction θ=0.5. Between this 
two extremes, are loci exhibiting some degree of linkage with a θ value somewhere 
between 0 and 0.5. 
 
First step in a linkage study is to genotype all individuals for a number of polymorphic 
DNA markers with known genomic position. Polymorphic microsatellite markers or 
SNPs can be used for this purpose. Genotype data is then analysed using a statistical 
test to search for evidence of linkage between markers and a putative disease loci  
 
Two main variants of linkage analysis exist, parametric and non-parametric linkage 
analysis. The classic parametric, or model-based, analysis requires specification of a 
number of parameters such as mode of inheritance, penetrance, allele frequency etc. 
The parametric method can be very powerful if these parameters can be specified 
correctly. However, in complex diseases a correct genetic inheritance model and 
reliable estimations of other parameters can seldom be specified, resulting in low power 
when using parametric analysis. Instead, the non-parametric “model-free“ linkage 
analysis that makes no assumptions of inheritance model is the method of choice 
(Lander and Schork 1994). 
 
Non-parametric linkage (NPL) analysis is based on observations of affected relatives 
pairs (ARPs) sharing identical by descent (IBD) alleles located close to a disease locus 
more often than expected from random allele segregation. IBD means that two relatives 
have inherited not only the same allele variant (identical by state, IBS), but also 
fulfilling the condition that this allele is inherited from the same parent (IBD). 
According to Mendelian laws of inheritance, the probability for a sib-pair to share 2, 1 
or 0 alleles are 25%, 50% and 25% respectively (Figure 5). If the allele sharing 
distribution deviates from the expected, it might indicate linkage. Sib-pair analysis 
studies sib-pairs exclusively (Penrose 1935). The more powerful affected relative pairs 
method can utilize several kinds of relationship apart from sib-pairs, for example 
grandparent-grandchild, cousins, avuncular and half-sibs (Haines and Pericak Vance 
1998). 
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Figure 5. IBD-sharing possibilies in a sib-pair and the expected frequencies of sharing 
2, 1 or 0 IBD-alleles according to Mendelian laws of inheritance.  
 
 
CANDIDATE GENE APPROACH 
The candidate gene approach is a straightforward method to test a gene potentially 
contributing to a disease, by testing for association or mutation screening. Candidate 
genes can be either functional or positional. Functional candidate genes are identified 
based on having a potential role in a disease causing mechanism. Positional candidate 
genes are located in a region with linkage to the disease, but usually also have a 
suggested functional role in the pathogenesis. Identifying one functional candidate gene 
that turns out to be associated with a disease, can often lead to identification of other 
disease associated genes in the same pathway. Compared to linkage analysis, candidate 
gene approach with large sample size is often a more successful strategy to detect genes 
contributing with only a small risk (Kwon 2000).  
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4 EPIDEMIOLOGY AND RISK FACTORS 
 
CHANGING INCIDENCE 
In the early 1990s the pediatric surgeons in Sweden noticed a decreased frequency of 
IHPS patients. This observation was confirmed in epidemiological studies describing a 
sharp decline of IHPS incidence to approximately one third during a ten-year period 
(Hedbäck et al 2001, Persson et al 2001). Previously, several reports have described 
temporal variations of incidence in several regions, but not as remarkable as this (Webb 
et al 1983, Dodge 1975, Wallgren 1960, Kerr 1980, Grant and McAleer 1984, Sule et al 
2001, MacMahon 2006). The genetic background in a population can obviously not 
change over a few years, and cause a shift in incidence such as this. Instead, a change in 
the infant’s perinatal environment with removal of a risk factors, or addition of a 
protecting factor, would explain the decline in incidence. Geographical differences with 
almost three times higher incidence in south of Sweden compared to the north was also 
reported (Hedbäck 2001). A genetic explanation for these differences could be a 
founder effect, but more likely differences in environment. Apart from the Swedish 
reports, several other European countries or regions have also reported a similar pattern 
of decline in incidence (Nielsen et al 2000, Sommerfield 2008, Pedersen et al 2008). 
However, a few studied regions with an already low IHPS incidence during the 1980s 
remained unchanged (Pedersen et al 2008). 
 
 
RISK FACTORS 
Maternal factors and birthorder 
Several consistent reports have confirmed that infants to young mothers and first-borns 
have a higher risk to develop IHPS, also when controlling for bias between these two 
variables (Rasmussen et al 1989, Dodge 1975, Schechter et al 1997). Another SIDS 
risk factor also studied for IHPS, is maternal smoking. A Danish population based 
study showed a 2-fold increased IHPS risk for infants to smoking mothers compared to 
non-smokers (Sörensen 2002).  
 
Feeding practices 
A higher incidence of IHPS among bottle fed infants compared to breast fed has been 
reported in several studies (Habbick et al 1989, Webb et al 1983). However, occasional 
reports have also claimed the opposite (Dodge 1975). Curds formed from artificial milk 
formula interfering with or obstructing the pylorus is proposed as a possible mechanism 
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resulting in pyloric hypertrophy (Osifo and Evbuomwan 2009). A correlation between 
the frequency of feeding (3 or 4-hourly) and age at onset of symptoms is reported 
(Gerrard et al 1955). One can speculate if feeding practices, in terms of frequency and 
volume of each feeding, is of importance also for development of the disease and might 
differ between breast and bottle fed infants.  
 
Prone position 
A parallel incidence rate between SIDS and IHPS during the 1970s-1990s was 
previously described, suggesting a common risk factor for these disorders (Persson 
2001). The “back to sleep” campaign during the 1990s encouraging parents to let the 
infants sleep on their back, was attributed as the most important measure for decreasing 
the SIDS incidence. Therefore the prone position was also suggested as an IHPS risk 
factor. Feeding often precedes putting the infant to sleep, and therefore can different 
localization of stomach content in prone or back position might be of importance as a 
predisposing IHPS factor. In the back position, the given contrast was located in the 
fundus region, not interfering with the pyloric region. In the prone position, the contrast 
was instead accumulated in the pyloric antrum region, interfering with the pylorus and 
possibly exerting mechanical pressure to this region (Persson et al 2001). 
 
  
Prone position Back position 
Figure 6. Upper GI-study of infant lying in prone and back position. In the prone 
position the contrast is accumulated in the pyloric antrum. In the back position, the 
contrast is instead accumulated in the fundus region separated from the pyloric region. 
Pictures from Persson et al 2001. Reproduced with permission from Pediatrics, Vol 
108, Page E70, Copyright 2001 by the AAP. 
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The IHPS-SIDS study was later replicated in Scotland. This showed a decreased 
incidence for both SIDS and IHPS during the 1990s with linear correlation. However, 
the fall of IHPS incidence preceded the fall of SIDS incidence with 2 years. The 
authors therefore doubted the hypothesis of shared risk factors of IHPS and SIDS 
(Sommerfield 2008). However, the time lag between decreasing IHPS and SIDS 
incidence does not automatically exclude that prone position is a risk factor for IHPS, 
since prone position could be a stronger risk factor for IHPS than SIDS. The effect in 
terms of decreasing incidence would then be seen earlier for IHPS compared to SIDS. 
 
Erythromycin treatment 
A sudden increased number of IHPS cases were noticed in a hospital a few weeks after 
the newborns had received erythromycin prophylaxis due to a pertussis outbreak 
(Honein et al 1999). Further studies showed an up to 10-fold increased risk of IHPS 
among infants treated with Erythromycin within the first 2 weeks of life (Cooper et al 
2002, Mahon et al 2001).  
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5 PATHOGENESIS 
 
It is well established that both genetic and environmental factors influence development 
of IHPS, but the underlying pathogenesis resulting in pyloric hypertrophy is still not 
revealed. Several observations suggest that pyloric spasm is part of the mechanism 
resulting in pyloric hypertrophy. Molecular studies in this field have mainly focused on 
abnormal innervation of the pyloric muscle and altered expression of neurotransmitters 
mediating pyloric relaxation.  
 
 
PYLORIC SPASM 
Although uncommon, there are a few reports of infants with onset of IHPS symptoms 
virtually from the first feeding (Andrassy et al 1977, Geer et al 1985, Hatiboglu 1996). 
The initial radiological investigation has in such cases shown signs of pyloric spasm, 
but not hypertrophy of the pyloric muscle. With a repeated radiologic study a few days 
after, also pyloric hypertrophy has been detected and the infant has been diagnosed and 
cured with pyloromyotomy (Ng and Lee 2002). It is proposed that the process with 
pyloric spasm can start early, even prenatally, suggested by the finding of 
polyhydramnios and in-utero detected gastric dilation in a few fetuses presenting with 
IHPS shortly after birth (Houben and Kely 1997, Powell 1962, Zenn and Redo 1993, 
Katz et al 1988). However, the scientific evidence of these few cases should not be 
overestimated. In addition, early onset cases are uncommon and for the vast majority of 
patients the start of enteral feeding seems obligate for the development of the disease 
(Chung 2008). Less is known whether pyloric spasm precedes the hypertrophy also in 
these cases. Beneficial effect of medical treatment of IHPS with anticholinergic 
substances however indicates that pyloric spasm is involved in the pathogenesis. 
 
 
PYLORIC INNERVATION 
The pylorus is innervated by the enteric nervous system (ENS), also called “the second 
brain” indicating its complexity (Gershon 1999). The ENS is competent to operate 
autonomously through reflex circuits with sensory neurons detecting physiological 
conditions and motor neurons regulating peristalsis, absorption, blood flow and release 
of enzymes and hormones (Gershon 2005). However, under normal circumstances the 
ENS operates under influence of the central nervous system (CNS).  
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In functional terms, two different kinds of motor neurons mediates contraction 
(excitatory motor neuron) and relaxation (inhibitory motor neuron) of the gut. A large 
number of neurotransmitters and neuropeptides mediating these effects have been 
identified. Nitric oxide (NO) is the major neurotransmitter mediating relaxation (Bult et 
al 1990).  
 
Nitric oxide 
The neurotransmitter that has gained most attention in IHPS research is nitric oxide 
(NO), which is an important mediator of enteric smooth muscle relaxation (Desai et al 
1991, Bult et al 1990). NO is synthesized from L-arginine by nitric oxide synthase 
(NOS), an enzyme family including three different isoforms. Synthesis of NO in 
intestinal neurons is catalyzed by the neuronal nitric oxide synthase (nNOS) requiring a 
few co-factors including tetrahydrobiopterin (BH4). This is an interesting connection to 
the hph1-mouse model for pyloric stenosis (Abel et al 2004).  
 
Immunohistochemistry studies have shown absence or decreased density of nNOS 
containing nerve fibers in hypertrophic pyloric muscle, suggesting that the pyloric 
muscle hypertrophy is a result of abnormal innervation (reviewed by Hernanz-
Schulman 2003).  
 
 
ANIMAL MODELS 
Genetic modified animal models 
Two genetic modified animal models for IHPS are described, the Nos1-mouse and the 
hph-1 mouse. They exhibit two different genetic alterations both resulting in a final 
common pathway with deficient or absent NO synthesis.  
 
The Nos1 knock out mouse exhibits a phenotype with enlarged distended stomach and 
thickened pylorus regardless of fasting or being fed. Histologic examination shows 
hypertrophy of the circular muscle layer of the stomach and pylorus. As in IHPS, the 
pyloric hypertrophy causes gastric outlet obstruction. The remainder of the intestine 
and peripheral NOS-expressing tissue appeared normal (Huang et al 1993).  
 
The hph-1 mouse was originally created as a model of phenylketonuria caused of an 
induced error of BH4 metabolism. BH4 is a co-factor for both phenylalanine 
hydroxylase and NOS enzymes why BH4 deficiency in addition to 
hyperphenylalaninaemia results in decreased NOS activity and production of NO (Abel 
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et al 2004, Brand et al 1995, Giovanelli et al 1991). The hph1-mouse exhibits a 
phenotype resembling the IHPS features in human with transient pyloric muscle 
hypertrophy, distended stomach and failure to thrive which resolves as the pyloric 
muscle normalize (Abel et al 2004). Innervation and immunoreactivity for 
neurotransmitters has been reported normal (Abel et al 2004).  
 
Pentagastrin induced pyloric stenosis 
Administration of pentagstrin to canine fetuses or pups can produce pyloric stenosis 
and to a lesser extent also pyloroduodenal ulcers. The histological feature of the pyloric 
hypertrophy resembles those found in human form of IHPS (Dodge and Karim 1976)  
The mechanism by which pentagastrin induce pyloric hypertrophy is uncertain but 
several mechanisms are possible. Pentagastrin is known to stimulate antral motility 
(Misiewicz et al 1969) which could contribute to pyloric spasm. Pentagastrin also 
stimulates acid secretion, which stimulates a release of secretin and cholecystokinin 
that stimulate gastric contractions, possibly ending up with pyloric spasm (Rogers et al 
1975).  
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6 AIMS 
 
The general aim of this thesis was to investigate the genetic and environmental risk 
factors predisposing for IHPS.  
 
The specific aims were: 
 
• To study two candidate genes for IHPS (MLN in study I and NOS1 in study II) 
 
• To unbiased localize predisposing loci for IHPS by genome-wide linkage 
analysis (Study III) 
 
• To study IHPS incidence in Sweden and analyse maternal and perinatal 
characteristics as risk factors for IHPS (Study IV) 
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7 MATERIALS 
 
GENETIC STUDIES 
Patients recruited to the genetic studies I-III were identified from the pediatric surgery 
clinics in Stockholm, Uppsala, Lund and Göteborg where the patients were treated for 
IHPS from 1971 and onward. In a questionnaire we asked for occurrence of more 
known IHPS affected individuals in the family. If no heredity was revealed, the patient 
was classified as a sporadic case. The families with positive heredity were interviewed 
for pedigree mapping, and all family members were offered to participate in the study. 
Genomic DNA was isolated from venous blood samples or from skin fibroblast cells 
from skin biopsies collected at surgery with pyloromyotomy. 
 
In collaboration with University College London Institute of Child Health, the Swedish 
material of families in study III was extended with DNA samples from British IHPS 
families. A population based control group consisting of randomly selected healthy and 
anonymous blood-donors from the Stockholm region was used as controls in study I 
and II. 
 
Study populations 
In study I, 57 IHPS cases (22 familial and 35 sporadic) were used for mutation 
screening and genotyping of MLN. Also, the family of one familial case including 4 
additional individuals (1 affected, 3 not affected) was analysed due to sequence variant 
in the proband. The control group consisted of 184 randomly selected controls. 
 
In study II, 82 IHPS cases (54 familial and 28 sporadic) were genotyped for the NOS1 
exon 1c promoter polymorphism. The control group consisted of 80 randomly selected 
controls. 
 
In study III, 37 Swedish families with at least two IHPS affected members (184 
individuals, 92 affected, 58 affected relative pairs) were included for genome-wide 
scan. Ratio of affected boys to girls was 1.7:1. Figure 7 shows the pedigrees of the 
Swedish families. 
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To extend the Swedish material, 31 additional British families (256 individuals, 101 
affected, 126 affected relative pairs) were included for specific analysis of the fine 
mapping regions. Ratio of affected boys to girls was 3:1.  
 
 
 
Figure 7. Pedigrees of the 37 Swedish families included in the genome-wide linkage 
study. DNA was available from all affected and total 184 individuals. 
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EPIDEMIOLOGICAL STUDY 
Registers 
The Swedish National Patient Register (NPR) held by the Swedish National Board of 
Health and Welfare, contains prospectively collected data of all hospitalizations in 
Sweden. NPR was founded in 1964 and included at that time only 6 of the 26 Swedish 
counties. Since then has the number of included counties gradually increased, and the 
register reached full coverage in 1987 when all 26 counties were included. The main 
purposes of the register are to provide data for health care evaluation, statistics and 
research. NPR data includes patient’s personal registration number, geographical data, 
date of admission and discharge, procedures, and main and secondary diagnosis coded 
according to the ICD-classifications. The quality of data is extremely good with a drop 
out rate of less than 2% of all hospitalizations (Kvalitet och innehåll i patientregistret 
2009).  
 
The Swedish Medical Birth Register held by the Swedish National Board of Health 
and Welfare, is a nationwide register founded in 1973 containing data of all 
pregnancies in Sweden leading to deliveries. Register data includes prospectively 
collected information of both the pregnant woman and the newborn infant, registered at 
the antenatal clinic, delivery and neonatal units up to one month after birth. Register 
variables includes personal registration numbers, maternal age and parity, maternal 
weight, length and ethnicity, exposures during pregnancy such as smoking, chronic or 
relevant diseases, single or multiple birth, duration of pregnancy, delivery record, birth 
weight and possible diagnosis of the infant. Reporting is also good with only 1-3 % of 
infants missing (Medicinska Födelseregistret). 
 
Study population 
In study IV, from the Swedish Patient register we identified all individuals treated as in-
patients with IHPS as main or secondary discharge diagnosis during the period 1973-
2008 (ICD-8 code 750.10, ICD-9 code 750F, ICD-10 code Q40.0). Further inclusion 
criteria were diagnosis before 1 year of age, since cases beyond this age most probably 
have as a misclassified diagnosis, and being born in Sweden to assure data from the 
Medical birth register. A total of 4797 cases were identified with these criteria during 
the study period. Flowchart of the study participants is shown in Figure 8.  
 
To further reduce risk of including patients with misclassified diagnosis, patients not 
surgically treated with pyloromyotomy or a similar procedure (surgical procedure code 
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4410, 4464, 4499, JDH60, JDH61, JDH63, JDH00) were excluded from the study. 
After exclusion of 1001 conservative treated patients, 3796 cases remained.  
 
For multiple births, there is a known risk that a twin’s medical birth register form 
instead contains information of its twin sibling. This motivated exclusion of twins for 
the case control part of the study. After exclusion of 188 twin cases and 1397 controls 
(twin control or control corresponding to excluded twin), 3608 cases and 17588 
controls remained as the final cohort for case control study. 
 
 
ETHICAL PERMISSIONS 
The genetic studies were approved by the Ethics Committee of Karolinska Institutet, 
and the Ethics Committee of University College London Hospital. Informed consent 
was obtained from all Swedish and British participating individuals. 
 
The epidemiological study was approved by the Ethics Committee of Karolinska 
Institutet. 
 26 
 
 
 
 
 
Figure 8. Flowchart of cases and controls included in study IV. 
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8 METHODS 
 
GENETIC STUDIES 
DNA isolation 
Genomic DNA for study I-III was isolated from peripheral blood samples or skin 
fibroblast cells using a standard protocol. 
 
DNA sequencing 
Sequencing was used for genotyping and mutation screening of candidate genes in 
study I, II and III. Fragments to be sequenced were amplified with polymerase chain 
reactions (PCR) using primers flanking the fragments. Primer sequences and PCR 
conditions are available on request. PCR products were purified and then used for 
sequencing reaction using ABI PRISM BigDye Terminator v1.1 Cycle Sequencing kit 
(Applied Biosystems, Foster City, CA, USA) according to manufacturer’s 
recommendations. Sequence data were analyzed on ABI 310, ABI 3100 ABI 3110 or 
ABI 3730 (Applied Biosystems). Chromatograms were generated using Sequencing 
analysis (Applied Biosystems). 
 
In study I, all five MLN exons were sequenced for mutation screening and genotyping. 
In study II, the NOS1 exon 1c promoter region was sequenced for genotyping. 
Mutation screening of the candidate genes NPY and GCN in study III was performed 
by sequencing all NPY exons and only exon 5 in GCN gene. This exon codes for the 
part of the proglucagone protein corresponding to GLP-2 after cleavage of the 
prohormone. 
 
Statistical test for association 
In study I, test for statistical significant association between MLN p.Val15Ala 
polymorphism and IHPS was performed using chi-square (χ2) test. P-value <0.05 was 
considered to be statistically significant. 
 
In study II, test for statistical significant association between NOS1 1c promoter 
polymorphism and IHPS was assessed using logistic regression analysis. Risks 
associated with variant genotypes were calculated and expressed as odds ratios (ORs) 
with 95% confidence intervals (CIs). 
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Linkage analysis 
In study III microsatellite based genome-wide linkage analysis and fine mapping was 
performed. The principles and theoretical background of linkage analysis is discussed 
in chapter 3.  
 
Genotyping genome-wide scan 
All individuals in the Swedish families were genotyped with 353 fluorescent-labeled 
microsatellite markers evenly distributed over the 22 autosomes and the X 
chromosome. The marker set was based on the Weber 6 screening set (Sheffield et al 
1995). In sparsely covered regions additional markers were added from the Genome 
Database and Marshfield Medical Research foundation. Mean inter marker distance for 
the initial genome wide scan was 10.24 cM and the mean heterozygosity rate was 0.76. 
Each marker was amplified in separate PCR reactions. PCR conditions and marker list 
are available on request. Up to five markers from each and same individual were 
pooled and then size fractioned on an ABI 377 DNA Sequencer or ABI 3730 DNA 
analyzer (Applied Biosystems). The resulting electrophoretic data was analysed with 
Genescan 3.1.2 / Genotyper2.0 software (Applied Biosystems). Success rate for 
genotyped markers were 80%.  
 
Genotyping fine-mapping 
Fine-mapping markers were selected from the Genome Database and Marshfield 
Medical Research foundation. For fine mapping of the loci on chromosome 2p, 2q, 6p, 
7p, 8q, 12q and 13q a set of 6, 4, 11, 10, 2, 2 and 6 markers were added, respectively. 
Also, two markers on chromosome 16p were added due to a recently published report 
of linkage in this region (Capon 2006). Average marker density of the fine mapped 
regions was 2.9 cM. PCR, size fractioning and analysis of electrophoretic data were 
performed as for the initial genome wide scan. Obtained fine-mapping results were 
added to the genome-wide scan data set, and NPL analysis was reanalysed for the 
chromosomes including fine mapping regions. 
 
Statistical analysis 
Non parameteric linkage (NPL) analysis with affected relative pairs method was used 
since mode of inheritance is unknown. Analysis was performed in Allegro software 
version 1.2 (Gudbjartsson et al 2000) with option arguments for linear statistics and Sall 
scoring function. The majority of the pedigrees in the Swedish material are relatively 
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small and homogene in structure with 2-3 affected, which motivates the use of a 
statistical model with equal weight assigned to all pedigrees. However, the material 
also includes a few extended pedigrees with up to 5 affected individuals. If an equal 
weight model is used, there is a risk that these families exert excessive influence on the 
total result because of their higher information content. An extended pedigree alone 
could then give a NPL peak that falsely seems to be valid for the whole material. This 
motivates instead the use of a statistical model where a weighting scheme is applied to 
all pedigrees to compensate for different pedigree structures. We choosed to analyse 
data with both an equal weighted model and a model with weighting factor power 0.5, 
and evaluate possible differences between these two analyses. 
 
Simulations 
The threshold value for significant linkage using NPL score is dependent on the 
pedigree structures included in the study material. Therefore, for each study performed 
the specific threshold value has to be determined by either simulations or theoretical 
approximations. We performed simulations and defined cut off values for suggestive 
and significant genome-wide linkage using Lander Kruglyak’s criteria (Lander and 
Kruglyak 1995). Significant linkage equals the NPL score occurring by chance at any 
chromosomal position in average 0.05 times per genome-wide scan. Threshold value 
for suggestive linkage equals the score randomly occurring once per genome scan.  
 
Genotype data for 10 000 genome-wide scans were simulated using Allegro software 
(Gudbjartsson et al 2000). The simulation marker set included both the genome-wide 
scan and fine mapping markers. Pedigrees had identical structure and individuals the 
same affection status as in the original material. The simulated genotypes had identical, 
success rate and allele frequencies as in the original analysis. Only individuals having 
genotype data in the original analysis were assigned genotype data in the simulations.  
 
The 10 000 simulated sets of genome-wide genotype data were analysed in Allegro 
software (Gudbjartsson et al 2000) using the same settings as in the original analysis. 
Analysis was performed with both equal weight and power0.5 statistics. The NPL-
score that occurred in average 0.05 times per simulated genome-wide scan for each 
statistical model was defined as the threshold NPL-score for significant linkage. 
Threshold value for suggestive linkage was defined as the NPL-score occurring in 
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average once per simulated genome-wide scan. Double peaks of a NPL score were not 
considered independent if they occurred within 20 cM of each other. 
 
Candidate regions and identification of candidate genes 
Candidate regions for loci showing evidence in favour of linkage were pragmatically 
defined as the region exhibiting NPL-score exceeding the regions maximum NPL-score 
minus 1 unit (NPLmax-1). 
 
The function and expression pattern of genes located in the candidate regions were 
investigated by mining the Ensembl and NCBI databases. In addition, the gene 
prioritizing software Endeavour (Aerts 2006, Tranchevent et al 2008) was used as a 
tool in the search of candidate genes located in the candidate regions. Candidate genes 
were screened for mutations as previously described.  
 
 
STATISTICAL ANALYSES IN EPIDEMIOLOGY STUDY 
Study design was a nationwide population based register study using data from the 
period 1973-2008. Analysis included both descriptive analysis and a case control study. 
All analyses were performed using Stata 11.0 for Mac OS software (StataCorp, College 
station, TX, USA). 
 
Descriptive analysis 
Annual incidence of IHPS was calculated as rate per 1000 live births. Data of annual 
birth numbers were obtained from Statistics Sweden. Incidence was calculated for the 
total cohort and stratified by gender. Nationwide data from NPR is only available from 
1987 and onward. To get an indication of nationwide incidence before 1987, incidence 
rate in Stockholm was used as an estimate since NPR covered all Stockholm hospitals 
since 1973. Incidence data presented in Figure 10 was adjusted for year 2008 age 
distribution using Poisson regression.  
 
Based on incidence rate, three obvious periods with high, declining and low incidence 
could be defined:  
• 1973-1988 high incidence  
• 1989-1997 declining incidence  
• 1998-2008 low incidence. 
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Age at diagnosis was defined as age in weeks at first admission with diagnosis IHPS 
and categorized into two-weeks groups.  
 
Distribution of gender, twin births and age at diagnosis were calculated for the 
cumulative study period, and for each of the three periods corresponding to high (1973-
1988), declining (1989-1997) and low incidence (1998-2008). 
 
Case-control study 
Study variables from Medical Birth Register were categorized for statistical analysis as 
shown in Table 2.  
 
Association between each of the study variables and IHPS risk was analysed using 
conditional logistic regression, conditioned on birth year, sex and birth county. Relative 
risks were calculated and expressed as odds ratios (ORs) with 95% confidence intervals 
(CI). Data was analysed with both a univariate and a multivariable model to include 
adjustment for covariates that could be possible confounders. 
 
Three sub analyses were performed with multivariable analysis stratified by time 
period, gender and age at diagnosis. The breakpoint for early/late diagnosis was defined 
as the median value for age at diagnosis. Trends in ORs over time was analysed using 
logistic regression stratified by time period (time periods corresponding to high, 
decreasing and low incidence). 
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Table 2. Categorization of study variables from Medical Birth Register 
Birthorder First, second, third or fourth and more born. 
Gestational age <35 completed weeks (Very Preterm)  
35-36 weeks (Preterm) 
37-41 weeks (Term) 
≥42 weeks (Postterm) 
Birth weight for gestational age <5th percentile  
5-9.9th percentile  
 10-89.9th percentile 
90-94.9th percentile 
≥95th percentile 
Neonatal jaundice Occurrence of ICD classification code for 
neonatal jaundice (haemolytic jaundice excluded) 
ICD-10: P570, P578-585, P589-590, P592-593, 
P598-599, R179  
ICD-9: 773A-C, 773E-F, 774A-D, 774E-F, 
774G-H  
ICD-8: 77400, 77410, 77420, 77429, 77497, 
77499, 77893, 77894, 77896) 
Pre-pregnant BMI <18.5 (Underweight)  
18.5-24.9 (Normal weight)  
25-29.9 (Overweight)  
30- (Obese) 
Maternal age <20 years  
20-24 years  
25-29 years  
30-34 years  
35 years and older 
Labour 
 
Vaginal birth  
Caesarean section 
Maternal smoking* 
 
* during early pregnancy 
Non-smoker  
< 9 daily cigarettes  
≥10 daily cigarettes 
Maternal birth country Nordic  
Non-Nordic 
Maternal diabetes Occurrence of ICD classification code for 
diabetes mellitus or gestational diabetes mellitus: 
ICD-10: E100-149, O240-244, O249 
ICD-9: 250A-H, 648A, 648W  
ICD-8: 25000-25009 
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9 RESULTS AND DISCUSSION 
 
MUTATION SCREENING OF THE MLN GENE  
We proposed motilin (MLN) as an IHPS candidate gene, since treatment with the 
motilin agonist erythromycin increases risk for IHPS (Cooper and Griffin 2002, Mahon 
et al 2001, Peeters et al 1989). Motilin is a gastrointestinal hormone released from 
intestinal mucosa cells, causing intense gastric contractions migrating to the intestine 
(Jadcherla et al 1997). Our hypothesis was that motilin could induce pyloric spasm in 
the immature pylorus, resulting in pyloric hypertrophy. All coding exons of the MLN 
gene were screened for mutations. Using a case control design, allele frequencies of the 
MLN polymorphism rs2281820 (p.Val15Ala) was assessed for association with the 
disease. 
 
Sequencing of the MLN gene revealed three previously not reported sequence 
variations, all present in both patients and controls (Table 3). One of the variants, 
c.74C>G was a missense variation exchanging an alanine to glycine (p.Ala25Gly) at 
the last position in the motilin prohormone’s signal peptide. The patient exhibiting this 
variant was a familial case, which prompted mutation testing of the c.74C>G variant in 
the rest of that family including one additional affected individual and three additional 
not affected individuals. The result showed that c.74C>G variant did not co-segregate 
with the disease. Screening the whole gene in all family members detected the c.-
66C>T variant, which also did not segregated with the disease. Heterozygote 
frequencies of the detected sequence variants in cases and controls are shown in Table 
3. No significant differences of the heterozygote frequencies were detected.  
 
Table 3. Heterozygote frequencies of detected novel sequence variants 
Sequence 
variant 
Familial * 
(n=23) 
Sporadic 
(n=35) 
Total cases* 
n=58 
Controls* 
n=187 
Variant 
type 
Aminoacid 
change 
c.-66C>T 1 0 1 (1.7%) 3 (1.6%) 5’-UTR - 
c.74C>G 1 0 1 (1.7%) 1 (0.5%) Missense Ala25Gly 
c.489C>T 0 2 2 (3.4%) 15 (8%) 3’-UTR - 
* Additional family members from mutation screened family included 
 
 
Genotype and allele frequencies of the p.Ala25Gly polymorphism in patients and 
controls are listed in Table 4. C-allele homozygotes were more frequent and C-allele 
frequency was higher among cases than controls, but these differences were not 
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significant (χ2 test p >0.05). Also, when stratifying cases into familial and sporadic 
cases no significant differences were detected (χ2 test p >0.05). 
 
Table 4. Genotype and allele frequencies of MLN rs2281820 polymorphism in cases 
and controls. 
Genotype Familial cases 
(n=22) 
Sporadic cases 
(n=35) 
Cases total  
(n=57) 
Controls  
(n=184) 
C/C 11 (50%) 15 (43%) 26 (46%) 65 (35%) 
C/T 9 (41%) 13 (37%) 22 (39%) 94 (51%) 
T/T 2 (9%) 7 (20%) 9 (16%) 25 (14%) 
Allele     
C 31 (70%) 43 (61%) 74 (65%) 224 (61%) 
T 13 (30%) 27 (39%) 40 (35%) 144 (39%) 
 
These results do not support MLN gene mutations or the p.Ala25Gly polymorphism to 
play a major role in the IHPS pathogenesis. However, a polymorphism contributing 
only with a minor risk would require a large sample size to detect significant 
association. According to our hypothesis that motilin induces pyloric spasm, the 
putative MLN gene variation causing this would presumptively have a gain of function 
effect. The most probable mechanism causing this would be an alteration in the MLN 
gene’s regulatory region. Therefore, the promoter region should also be investigated in 
a future study before MLN is dismissed as a candidate gene. Another feasible 
mechanism for involvement of the motilin pathway in IHPS pathogenesis, is changes in 
the motilin receptor. However, the motilin receptor gene (MLNR) has been screened for 
mutations in a British material without any positive findings (Chung, personal 
communication).  
 
 
ASSOCIATION STUDY OF A NOS1 PROMOTER POLYMORPHISM  
A polymorphism in the NOS1 exon 1c promoter (c.-84G>A) was previously suggested 
to be associated with IHPS (Saur et al 2004). This variant is a functional SNP where the 
A-allele reduces the expression of the NOS1C isoform, and it has also been associated 
to IHPS. This prompted us to study the promoter c.-84 SNP for association with IHPS 
in our Swedish material.  
 
Genotype and allelic association for the c.-84 SNP with IHPS was assessed for the total 
patient group compared to controls, for familial and sporadic cases separately 
compared to controls, and finally in a multivariate model with adjustment for gender 
and familial inheritance. Homozygote G-allele carriers were more frequent among 
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cases compared to controls, but no significant allelic association could be detected. 
Comparing homozygote G-allele carriers and G/A carriers, detected with borderline 
significance a lower frequency of A-allele carriers among cases than controls (OR 0.47; 
95% CI 0.21-1.00). No significance was found for either genotype or allelic association 
when cases were stratified into familiar and sporadic cases, or in the multivariate 
model.  
 
Table 5. Genotype frequencies of NOS1 SNP rs41279104 in cases and controls 
Genotype  Familial cases 
(n=54) 
Sporadic cases 
(n=28) 
Cases total 
(n=82) 
Controls  
(n=80) 
G/G 46 (85%) 23 (82%) 69 (84%) 57 (71%) 
A/G 7 (13%) 5 (18%) 12 (15%) 23 (29%) 
A/A 1 (2%) 0 1 (1%) 0 
Allele     
G 99 (92%) 51 (91%) 150 (91%) 137 (86%) 
A 9 (8%) 5 (9%) 14 (10%) 23 (14%) 
 
Contrary to previous finding of association between c.-84A SNP and IHPS (Saur et al 
2004), we found with borderline significance association to the heterozygote G/G 
genotype when compared to A/G carriers (OR 0.47 95% CI 0.21-1.00). There are 
several possible explanations for the diverging results. The sample size in the study 
from Sauer et al was very small and included only 16 patients, that also originated from 
another population compared to our study. Following our publication yet another 
replication study was performed in an Asian population that confirmed lack of 
association between the c.-84 SNP and IHPS (Miao et al 2010). The NOS1 gene is one 
of the most complex human genes regarding promoter diversity, why further regulatory 
mechanisms except from the c.-84 SNP must be considered.  
 
 
GENOME-WIDE LINKAGE ANALYSIS AND FINE-MAPPING  
The genetic influence on development of IHPS is well established. In order to 
unconditionally identify IHPS loci we performed a genome wide linkage study in 
Swedish IHPS families, using non-parametric linkage (NPL) analysis with affected 
relative pairs method. Statistical analysis was performed using two different models 
assigning equal weight to all pedigrees or applying a weighting scheme power 0.5 to 
control for different pedigree structures. Chromosomal regions exhibiting the highest 
NPL scores in the genome-wide scan were further studied by adding additional fine 
mapping markers and extension of the material with additional British families. 
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The initial genome-wide scan of the Swedish material revealed seven regions of 
interest for further fine mapping. Regions on chromosome 2q, 7p, 8q and 13q were 
implicated from statistical analyses with both equal weight and weighted analysis. 12q 
was proposed from the equal weighted analysis, and 6p from the weighted analysis.  
 
Table 6. Fine mapping regions, position determined by flanking fine mapping markers. 
Chromosome Cytogenetic location Position (cM)* Flanking markers 
2 2p23.3-2p21 49.6**  - 68.84 D2S2144  D2S2298 
2 2q23.3-2q31.1 159.43** - 177.98 D2S2299  D2S335 
6 6p25.2-6p21.1 11.3        - 68.9** D6S1617   D6S1650 
7 7p22.3-7p14.3 3.5**       - 47.84 D7S1532  D7S2496 
8 8q24.21 132.43**  - 135.57** D8S1774   D8S1801 
12 12q24.22-12q24.23 136.23**  - 139.04** D12S2082  D12S385 
13 13q12.13-13q14.13 17.41   - 50.11** D13S1254  D13S1312 
*Based on deCODE map **Position missing in deCODE map, position estimated based on Marshfield 
map  
 
Fine mapping enhanced the NPL score in five of the seven fine mapped regions, 
presented in Figure 2. Threshold values for suggestive and significant linkage were 
defined using material specific simulations according to Lander Kruglyak’s criteria. 
This provided evidence in favor of significant or suggestive linkage to four loci: 
 
• 2q24.3 evidence of significant linkage in equal and weighted analysis 
• 7p21.3-7p22.2 , evidence of significant linkage in the weighted analysis and 
suggestive linkage in the equal analysis. 
• 6p21.31 evidence of suggestive linkage in weighted analysis 
• 12q24.23 evidence of suggestive linkage in the equal weight analysis 
 
 
Table 7. Fine mapping results, equal weight analysis. Marker and highest NPL score 
from each fine-mapped region reaching NPL>1.5  is listed. 
Chr Cytogenetic 
location 
Marker Position (cM)* NPL-score Significance defined by 
simulations 
2 2q24.3 D2S111 171 3.10 Significant linkage (NPL >3.04) 
7 7p22.2 D7S1532 3.5** 2.98 Suggestive linkage (NPL >2.18) 
12 12q24.23 D12S366 137.36 2.63 Suggestive linkage (NPL >2.18) 
13 13q12.2 D13S1244 18.72 1.75 n.s 
6 6p24.3 D6S470 23.75 1.65 n.s 
* Based on deCODE map; ** Position missing in deCODE map, estimated position based on Marshfield 
map; n.s non significant 
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Table 8. Fine mapping results, weighted analysis. Marker and NPL score from each 
fine-mapped region reaching NPL>1.5  is listed. 
Chr Cytogenetic 
location 
Marker Position (cM)* NPL-score Significance defined by 
simulations 
7 7p21.3 D7S2514 14.94 4.55 Significant linkage (NPL >3.46) 
2 2q24.3 D2S111 171 3.77 Significant linkage (NPL >3.46) 
6 6p21.31 D6S1568 53.85 2.97 Suggestive linkage (NPL >2.69) 
13 13q12.3 D13S217 22.17 2.55 n.s 
2 2p22.3 D2S1788 58.96** 2.16 n.s 
* Based on deCODE map; ** Position missing in deCODE map, estimated position based on Marshfield 
map; n.s non significant; n.s non significant 
 
 
  
  
Figure 9. Chromosomal regions exhibiting significant or suggestive linkage after fine-
mapping using equal weight or weighted analysis.  
NPL threshold for significant linkage: 3.04 (equal analysis), 3.46 (weighted analysis) 
NPL threshold for suggestive linkage: 2.18 (equal analysis), 2.60 (weighted analysis) 
 
Interestingly, previously proposed IHPS candidate genes NOS1 (12q24.22) and MLN 
(6p21.31) are located in two of the regions showing evidence in favour of linkage. 
Further mining of these loci and their most adjacent regions for novel candidate genes, 
identified neuropeptide Y (NPY) and GLP-2 (coded by the glucagon gene GCN) as two 
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interesting functional candidates. However, mutation screening of NPY and exon 5 
GCN did not identify any obvious pathological mutations.  
 
Reanalysis of the fine-mapped regions with the material extended with British families 
failed to reach the same level of NPL-score as in the analysis including only the 
Swedish material.  
 
Two different strategies to continue mapping of potential candidate regions from a 
genome-wide scan are to either extend the material by adding more families, or to fine-
map the regions by adding more dense markers. Additional markers gives more 
information that can enhance the resulting NPL-score, provided the markers from 
initial analysis was not fully informative and true linkage exists. It can also narrow the 
susceptibility region making the search for candidate genes more precise (Haines 1998, 
Lander Kruglyak 1995). 
 
In our study, all available Swedish IHPS families were included already in the initial 
genome-wide scan. Extending the material would therefore imply inclusion of families 
from another population. So as a first step we performed fine mapping with more dense 
markers using the Swedish material. This enhanced the NPL scores in five of the seven 
fine-mapped regions, supporting existence of linkage in these regions. Four loci 
exceeded threshold value for genome-wide significant or suggestive linkage. 
 
The definition of significant genome-wide linkage according to Lander and Kruglyak 
means a less than 5% risk of a NPL-score in the genome-wide scan reaching the 
threshold value for linkage by coincidence. The threshold for suggestive linkage is 
reached at one point along the chromosomes in average once per genome-wide scan 
(Lander and Kruglyak1995).  
 
In our results, loci at 2q24.3 and 7p21.3-7p22.2 reached significant or suggestive 
linkage in both statistical models used. The locus 12q24.23 harboring the NOS1 gene, 
exhibits suggestive linkage in the equal, but not weighted analysis. This indicates that 
possibly one or a few of the extended families alone contributes to the NPL-score peak, 
an effect being compensated for and therefore disappears in the weighted analysis. It is 
implicated to separately analyse the contribution from each family at this locus in a 
future study. This can possibly identify further families exhibiting linkage to the NOS1 
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gene as shown by Chung et al (1996). It is unclear why the locus on chromosome 
6p21.31 exhibits suggestive linkage in the weighted analysis alone, and not in the equal 
weight analysis. 
 
Finally, extending the material with additional British IHPS families in the regions 
where the Swedish material showed linkage, did not enhance the NPL-score. This 
could of course be due to false positive results in the Swedish study, but also due to 
differences between the genetic backgrounds of the two populations represented in the 
samples. The importance of different genes contributing to a disease can apparently 
differ within a population, and this is likely to be even more apparent between different 
populations.   
 
In conclusion, we have identified three novel IHPS loci on chromosome 2q, 6p, and 7p.  
Also, a loci on chromosome 12q previously reported with evidence of linkage was 
confirmed with suggestive linkage in our material.  
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EPIDEMIOLOGICAL STUDY OF IHPS RISK FACTORS 
A rapid and pronounced decline in IHPS incidence during the 1990s implies a major 
change of one or multiple environmental risk factors during this period (Persson 2001, 
Hedbäck 2001, Sommerfield 2008). We performed a nation wide population study 
based on register data from Swedish National Patient Register (NPR) and Swedish 
Medical Birth Register to study the incidence and analyse maternal and perinatal 
characteristics as IHPS risk factors. To evaluate any changes of risk factors possibly 
causing the decline in IHPS incidence, trends in ORs were analysed over time. The 
skew gender distribution with predominance of boys, implied analysis stratified for 
gender to assess if risk factors differ between boys and girls. Also, analysis was 
stratified for age at diagnosis to evaluate differences in characteristics for infants with 
early or late onset of disease.  
 
The study cohort consisted of 3796 surgically treated IHPS cases born and diagnosed 
1973-2008, and 18985 matched controls. Twins were excluded from the case-control 
part of the study since they do not have reliable data from Medical Birth register. After 
exclusion of twins, 3608 cases and 17588 controls remained for the case-control study.  
 
Descriptive analysis 
The nationwide IHPS incidence decreased to one fifth during the period 1988-1997 
(2.25 to 0.43 per 1000 live births) and then remained constant at a low level around 
0.6/1000. Since NPR not has full national coverage until 1987, nationwide incidence 
data before 1987 was omitted. Stockholm, which has complete NPR data from 1973 
was instead used as a model to estimate nationwide incidence level before 1987. 
Incidence in Stockholm co-varied with nationwide incidence during time period 1987-
2008 (Figure 10). Three periods with high, declining and low incidence respectively, 
was defined (high incidence 1973-1988, declining incidence 1989-1997 and low 
incidence 1998-2008). Incidence stratified by gender showed a relatively constant sex 
ratio of 5-6:1 boys to girls independent of changing incidence (Figure 11).  
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Figure 10. Incidence of IHPS in Sweden and Stockholm. Nationwide data only 
available from 1987 and onward.  
 
 
 
Figure 11. Proportion of boys and girls among IHPS cases in Sweden 1973-2008. 
 
Median age at diagnosis was 5 weeks, and the majority of cases (>95%) were 
diagnosed before 13 weeks of age. Analysing age at diagnosis stratified for time 
periods, revealed a higher percentage of cases diagnosed before 5 weeks of age in 
recent years (Figure 12). Analysing age at diagnosis stratified for gestational age 
showed that very preterm infants presented later with the disease (Figure 13). There 
seems to be high number of very preterm infants diagnosed during first two weeks after 
birth. However, this is most probably due to a methodological error when registering 
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age at diagnosis. Very preterm infants are often admitted to the neonatal unit 
immediately after birth, and often stay for several weeks. If they are treated for IHPS 
during the hospitalization, they will falsely be registered for age at diagnosis the same 
day as they were admitted to the neonatal unit.  
 
 
Figure 12. Age at diagnosis for different time periods.  
 
 
Figure 13. Age at diagnosis for infants born very preterm, preterm, term or postterm. 
Very preterm infants presented later with the disease than all other groups.  
 
A higher frequency of twins was seen among cases (5%) compared to controls (2.5%).  
13% of the twin cases were concordant for the disease and all of these twin pairs had 
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the same gender (9 male twin pairs, 3 female twin pairs). However, data regarding 
zygosity is not included in the register and concordance for MZ and DZ twins 
separately were therefore not possible to evaluate.  
 
 
Figure 14. Annual number of IHPS cases surgically treated at a pediatric surgical clinic 
and general surgical clinic, respectively.  
 
A survey of which hospitals the IHPS patients were surgically treated at since 1987 was 
performed. This showed a trend of increased percentage of patients treated at pediatric 
surgery clinics in recent years. 
 
Case control study 
To assess a number of variables from Medical Birth Register as possible IHPS risk 
factors, cases were compared to controls using multivariate analysis. Two different 
models were used because data on smoking and BMI was not available for the whole 
study period. Model 1 includes the whole study period 1973-2008 but not the variables 
smoking and BMI. Model 2 includes data from 1982-1989 plus 1992-2008, and all 
study variables including smoking and BMI. Results from preferably model 2 are 
shortly commented below:  
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Table 9. Selected variables from multivariate analysis with adjusted ORs  
 Model 1, data from 1973-
2008 
Model 2, data 1982-89, 
1992-2008 
 Cases n=3608a Cases n=2353a 
 Controls n=17588a Controls n=11461a 
Variable OR (95% CI) OR (95% CI) 
   
Birth order   
1 1 1 
2 0.78 (0.71-0.85) 0.76 (0.67-0.86) 
3 0.81 (0.72-0.91) 0.77 (0.64-0.92) 
≥4 0.80 (0.67-0.96) 0.80 (0.62-1.03) 
   
Gestational age (weeks)   
Very preterm (<35) 2.09 (1.68-2.59) 1.44 (1.00-2.07) 
Preterm (35-36.9) 1.53 (1.29-1.82) 1.48 (1.15-1.90) 
Term (37-41.9) 1 1 
Postmature (42-) 0.94 (0.83-1.08) 0.82 (0.67-1.01) 
   
Labour   
Caesarean section 1.68 (1.52-1.86) 1.73 (1.50-2.01) 
Normal/vaginal birth 1 1 
   
Neonatal jaundice   
Yes 1.06 (0.88-1.27) 1.40 (1.07-1.82) 
No 1 1 
   
Maternal age (years)   
<20 1.42 (1.17-1.72) 1.24 (0.90-1.72) 
20-24 1.34 (1.21-1.47) 1.31 (1.13-1.52) 
25-29 1 1 
30-34 0.94 (0.85-1.03) 0.92 (0.80-1.07) 
35- 0.98 (0.86-1.12) 0.99 (0.83-1.19) 
   
Maternal smokingb (daily 
cigarettes)** 
  
None NA 1 
1-9  NA 1.62 (1.40-1.88) 
≥10 NA 1.66 (1.38-2.00) 
   
Maternal birth country   
Nordic 1 1 
Non-Nordic 0.50 (0.42-0.58) 0.58 (0.47-0.72) 
   
Abbreviations:   
a twins excluded; b maternal smoking during early pregnancy;  
**Data of smoking available from 1982; NA, non applicable 
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Birth order. Being first born was associated with an increased IHPS risk. Infants born 
as second or third child had a 23-24% decreased IHPS risk compared to being first 
born. 
 
Gestational age. Infants born before 37 weeks gestational age had an almost 50% 
increased IHPS risk. Categorizing this group into very preterm and preterm born 
infants, the very preterm group reached only borderline significance (OR 1.44; 95%; CI 
1.00-2.07) but the preterm group exhibited a significantly increased IHPS risk (OR 
1.48; 95% CI 1.15-1.90).  
 
Birth weight for gestational age. No significant difference in birth weight for 
gestational age was observed between cases and controls. 
 
Labour. Delivery with caesarean section was associated with 73% increased IHPS risk 
compared to vaginal birth. Indication (emergency or elective) for the performed 
caesareans was only available for a small percentage, thus further categorization and 
analysis of this group was not possible to perform. 
 
Neonatal jaundice. The risk of IHPS was increased with 40% in infants diagnosed 
with neonatal jaundice. However, neonatal jaundice did not reach significance as a risk 
factor in model 1. 
 
Maternal age. In model 1, a 34-42% increased risk for IHPS was noted for infants 
with mothers younger than 25 years. However, in model 2 only infants with mothers 
aged 20-24 had a significantly increased IHPS risk (OR 1.31; 95% CI 1.13-1.52). 
 
Prepregnant BMI. Infants to mothers with overweight exhibited a 19% increased 
IHPS risk (OR 1.19; 95% CI 1.03-1.36). Infants to mothers with underweight, normal 
weight and obesity had no increased risk. 
 
Maternal smoking was associated with an over 60% increased IHPS risk for the 
infant. A weak quantitative correlation between the number of daily cigarettes and ORs 
were noticed. 
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Ethnicity. Non-Nordic maternal birth country was associated with a 42% lower risk for 
IHPS.  
 
Diabetes. No association between IHPS risk and maternal diabetes was observed.  
 
Analysis stratified for time period, trends over time 
To assess changes in risk factors related to the changed IHPS incidence during the 
1990s, analysis stratified for time using the defined time periods for high, declining and 
low incidence, respectively, was performed. Main finding was that ORs for smoking 
significantly increased over time when incidence decreased. During the period with low 
incidence (1998-2008), infants to mothers who smoked ≥10 cigarettes daily had an 
over 2-fold increased risk for IHPS. Low birth rank reached not significance as a risk 
factor during the time period with high incidence (1982-1989), and prematurity failed 
to reach significance during the time period with low incidence. 
 
Analysis stratified for gender 
Analysis was stratified for gender to study if the risk factors had different influence on 
boys and girls. Analysis for girls rely on a very much lower number of cases compared 
to boys (366 girls vs. 1987 boys). Thus, results in the analysis stratified for girls are less 
likely to reach significance. This might explain why boys reach significance for several 
more study variables compared to girls.  
 
Birth rank as a risk factor, reached only significance among boys. Very preterms did 
not reach significance in either group. OR for prematures was higher among girls than 
boys, but not significantly (Girls: OR 2.03; 95%CI 1.08-3.78, Boys: OR 1.39; 95% CI 
1.05-1.83). Neonatal jaundice did not reach significance as a risk factor among girls, 
neither did young maternal age or maternal Nordic birth country.  
 
Analysis stratified for age at diagnosis 
Analysis stratified for age at diagnosis identified that being very preterm was a 
significantly higher risk factor among cases with late diagnosis (OR 2.66; 95% CI 1.55-
4.56) compared to early diagnosis (OR 0.81; 95% CI 0.47-1.39). 
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In summary we confirmed previous reports of a pronounced decreased incidence of 
IHPS in Sweden during the 1990s. The incidence has remained low and we can 
therefore state this not being a temporal variation. Whatever the cause for the decline in 
incidence, it seems to remain unchanged since end of the 1990s. The constant skew 
gender distribution supports a genetic background of the male predominance, even 
though environmental factors not can be excluded. A trend of earlier diagnosis is noted 
in recent years, and it is also obvious that very preterm born infants have a later onset 
of the disease.  
 
We confirmed the previously suggested risk factors low birth rank, prematurity, low 
maternal age and maternal smoking. Also, we identified a previously not reported 
association to caesarean section giving an over 70% increased risk for IHPS. The 
mechanism can only be speculated on. However, the risk is adjusted for possible 
confounders and the increased risk is stable when analysed over time and not differing 
between groups when stratified for gender and age at diagnosis. Association of being 
first born and IHPS can be possibly be explained by both maternal factors and other 
exposures such as infections etc from siblings.   
 
No published study so far, has analysed changing trends of risk factors over time. This 
could be an explanation why some studies from different time periods reach different 
conclusions. However, we found no major changes in environmental risk factors 
reflected in the study variables, that could explain the drop of incidence during the 
1990s. Though, maternal smoking was identified as a relatively more important risk 
factor in recent years during low incidence, giving a 2-fold increased risk IHPS risk. As 
in previous study by Sörensen 2002, we cannot from the registered data determine if 
smoking registered during early pregnancy was continued during the rest of the 
pregnancy and after delivery. Therefore the mechanism how smoking causes an 
increased IHPS risk is unclear.  
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10 CONCLUDING REMARKS 
 
In consistency with the multifactorial background of IHPS we have studied, and 
confirmed evidence of both genetic and environmental factors playing a role in the 
pathogenesis of IHPS.  
 
• Three novel chromosomal loci with evidence in favour of linkage were 
identified on chromosome 2q24.3 (NPL=3.10), 7p21.3 (NPL=4.55) and 
6p21.31 (NPL=2.95) in our Swedish material. We also confirmed a previous 
report of linkage to 12q24.23 (NPL=2.63) harboring the NOS1 gene. 
Interestingly, the MLN gene previously studied in a candidate gene approach 
study, is located in the chromosome 6 candidate region. 
 
• Candidate gene motilin (MLN) was studied without finding of mutations with 
obvious connection to the disease, or significant association of the p.Val15Ala 
polymorphism. This however, does not exclude the possibility of MLN playing 
a role in the pathogenesis of IHPS, especially since evidence of linkage was 
found to the chromosomal region harboring the MLN gene. In addition, the 
promoter region is not studied and also association of the p.Val15Ala 
polymorphism could be studied in a larger material.  
 
• A previously described association of NOS1 exon 1c polymorphism 
rs41279104 could not be confirmed in our material. Due to the complexity of 
the NOS1 gene, it is likely that alternative regulatory mechanisms apart from 
the studied polymorphism will be found that thus could explain the diverging 
results.  
 
• Caesarean section was identified as a novel risk factor for IHPS associated with 
an almost 80% increased risk for IHPS. Previously suggested risk factors as low 
birth rank, prematurity, jaundice, low maternal age and maternal smoking was 
confirmed. Smoking and primiparity were more important risk factors in recent 
years when IHPS incidence is low. Maternal smoking was associated with an 
two-fold increased IHPS risk. Association between prematurity and late onset 
of disease was identified.  
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11 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Infantil hypertrofisk pylorusstenos (IHPS) är en sjukdom som drabbar spädbarn upp till 
några månaders ålder. Detta tillstånd innebär att den nedre magmunnen, pylorus, blir 
kraftigt förtjockad och därmed utgör ett näst intill totalt passagehinder mellan magsäck 
och tolvfingertarm. De drabbade barnen insjuknar vanligen vid 3-8 v ålder med kraftiga 
kräkningar efter matning till följd av den trånga passagen mellan magsäck och tarm. 
Relativt omgående blir de drabbade barnen svårt uttorkade med karakteristiska 
rubbningar i saltbalansen. Sjukdomen botas med en operation, pyloromyotomi, då 
pylorusmuskeln klyvs vilket omedelbart botar barnet.   
 
IHPS drabbar omkring 1.5-3 per 1000 födda och är 5 ggr vanligare hos pojkar jämfört 
flickor. Förekomsten av sjukdomen minskade kraftigt under 1990-talet i Sverige och 
flera andra Europeiska regioner av oklar orsak. Dock är IHPS fortfarande en av de 
vanligaste indikationerna för kirurgi på spädbarn under första levnadsmånaderna.  
 
Det finns väl underbyggda bevis för att IHPS är en så kallad komplex sjukdom med 
multifaktoriell bakgrund, där både genetiska- och omgivningsfaktorer samt ett samspel 
mellan dessa bidrar till att sjukdomens utvecklas. Sjukdomens uppkomstmekanism är 
dock ej klarlagd, men mycket tyder på att en spasm (kramp) i pylorusmuskeln kan 
utlösa sjukdomen. Syftet med denna avhandling var att belysa och försöka klargöra 
genetiska- och omgivningsfaktorer associerade till sjukdomen. 
 
I studie I-III har två principiellt olika metoder använts för att leta efter sjukdomsgener, 
kandidatgensmetoden och kopplingsanalys. Vid kandidatgensmetoden utgår man från 
en tänkbar sjukdomsmekanism, och identifierar utifrån denna de sjukdomsgener som 
potentiellt kan vara av betydelse. Dessa så kallade kandidatgener screenas därefter för 
mutationer eller association mellan särskilda varianter av genen (polymorfier) och 
sjukdomen. Vid kopplingsanalys analyseras istället, förutsättningslöst och utan 
nödvändig förkunskap om sjukdomens uppkomstmekanism, hur genetiska markörer 
nedärvs i familjer med flera fall av sjukdomen. De kromosomregioner de sjuka ärvt 
gemensamt oftare än vad som kan förväntas orsakat av slumpen, kallas 
kandidatregioner och härbärgerar sjukdomsassocierade gener med en sannolikhet 
angiven som en ”sannolikhets score”.  
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Motilin är ett hormon i magtarm-kanalen som inducerar kontraktioner 
(muskelsammandragningar) i magsäck och tarm. I studie I identifierades motilin som 
en kandidatgen mot bakgrunden av att antibiotikabehandling med erytromycin före 2 v 
ålder ger en ökad risk för spädbarn att utveckla IHPS. Erytromycin har förutom dess 
antibakteriella effekt en sidoeffekt som motilin agonist, dvs den binder till 
motilinreceptorerna i tarmen och stimulerar receptorernas aktivitet. Hypotesen i studie I 
var därför att det kroppsegna motilin hormonet, liksom erytromycin, kunde vara 
delaktigt i uppkomsten av IHPS genom att framkalla spasm i pylorus. 
Mutationsscreening av motilingenen identifierade tre tidigare okända 
sekvensvariationer som dock ej hade någon tydlig koppling till sjukdomen. Vi kunde 
inte heller identifiera någon signifikant association till en tidigare känd polymorfi i 
motilingenen. 
 
Kvävemonoxid (NO) är en signalsubstans som medierar relaxation (avslappning) av 
glatt muskulatur bland annat i mag-tarm kanalen. NO i tarmens nervsystem bildas med 
hjälp av enzymet neuronalt kväveoxidsyntas (nNOS) som därför spelar en nyckelroll i 
den signalväg där en störning kan tänkas leda till pylorusspasm. En variant i nNOS 
genens (NOS1) regulatoriska region som påverkar hur mycket genen uttrycks, har 
tidigare visats vara associerad till IHPS. I studie II analyserades denna regulatoriska 
NOS1 polymorfi i vårt svenska material utan att vi kunde konfirmera tidigare påvisad 
association.  
 
Kopplingsanalys i 37 svenska familjer med minst två personer som behandlats för 
IHPS uppvisade koppling till regioner på kromosom 2, 6, 7 och 12. I dessa regioner 
återfinns intressant nog både motilin genen (kromosom 6) och nNOS genen (kromosom 
12). Utöver dessa identifierade vi ytterligare två kandidatgener som screenades för 
mutationer, NPY (kromosom 7) och GCG (kromosom 2), dock utan fynd med uppenbar 
koppling till sjukdomen.  
 
Den kraftigt minskade incidensen av IHPS under 1990-talet indikerar förändrad 
förekomst av en eller flera riskfaktorer under denna period. I syfte att studera 
incidensvariation och riskfaktorer utfördes i studie IV en registerstudie omfattande alla 
opererade IHPS fall i Sverige under perioden 1973-2008. Incidensen av IHPS föll till 
en femtedel under perioden 1988-1998, hela tiden med en väsentligen oförändrad 
könskvot 5:1 mellan pojkar och flickor. Kejsarsnitt, prematuritet (för tidigt född), 
gulsot under nyföddhetsperioden och att vara förstfödd i en syskonskara, var associerat 
med en ökad risk för IHPS i vårt material. Maternell rökning, ung moder och mor med 
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nordisk etnicitet var också associerat med en ökad risk för IHPS. Under senare år då 
IHPS incidensen varit låg konstaterades en ökad betydelse av rökning och primiparitet 
som riskfaktorer. Prematuritet var en högre riskfaktor för patienter med sent 
insjuknande jämfört insjuknande vid låg ålder. Denna studie är den första som påvisat 
ett samband mellan kejsarsnitt och risk för IHPS. 
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